MaaT Pharma lists on Euronext Paris

Hervé Affagard, co-Founder and Chief Executive Officer, opens the trading day in Paris.

MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors (in particular, acute myeloid leukemia) and acute graft-versus-host disease (GvHD).

The company has 3 products in the development phase.